#1
#1 out of 135.82%
health3h ago
Oncolytics Biotech Announces Positive Preclinical Data for Pelareorep with RAS-Targeted Agents
- Oncolytics Biotech reports initial preclinical data showing pelareorep with RAS inhibitors enhances anti-tumor activity.
- The company will pursue additional studies in pancreatic and colorectal cancer models to evaluate immune effects and resistance.
- Ongoing evaluations include combinations with KRAS G12C inhibitors and other RAS pathway agents in mutated models.
- Full dataset from the initial preclinical studies is expected to be presented in fall or winter 2026.
- The information stems from a TradingView News summary of ONCY’s SEC filings and disclosures.
- Oncolytics Biotech aims to advance pelareorep with RAS-targeted strategies into more studies.
- The development may target pancreatic ductal adenocarcinoma and colorectal cancer models specifically.
- The report notes ongoing evaluations include KRAS G12C inhibitors and next-generation RAS agents in RAS-mutated models.
- The fall/winter 2026 timeframe will reveal the complete preclinical data.
- The TradingView news summary attributes the information to ONCY’s filings and industry data.
Vote 0